<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neuronetics Inc — News on 6ix</title>
<link>https://6ix.com/company/neuronetics-inc</link>
<description>Latest news and press releases for Neuronetics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neuronetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c5aa78dffbe2df11ab58.webp</url>
<title>Neuronetics Inc</title>
<link>https://6ix.com/company/neuronetics-inc</link>
</image>
<item>
<title>Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to revi</description>
</item>
<item>
<title>Neuronetics Comments on Letter from Pointillist Family Office</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-comments-on-letter-from-pointillist-family-office</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-comments-on-letter-from-pointillist-family-office</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today issued the following response to the public letter to the Company’s Board of Directors (the “Board”) from Jorey Chernett at Pointillist Family Office published on April 6, 2026: T</description>
</item>
<item>
<title>Neuronetics Announces Chief Financial Officer Transition</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-chief-financial-officer-transition</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-chief-financial-officer-transition</guid>
<pubDate>Mon, 06 Apr 2026 20:30:00 GMT</pubDate>
<description>Reaffirms Fiscal Year 2026 Financial GuidanceMALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue</description>
</item>
<item>
<title>Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
<pubDate>Tue, 17 Mar 2026 11:50:00 GMT</pubDate>
<description>Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2</description>
</item>
<item>
<title>Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-appoints-dan-reuvers-as-president-and-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-appoints-dan-reuvers-as-president-and-chief-executive-officer</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple</description>
</item>
<item>
<title>Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call</guid>
<pubDate>Tue, 03 Mar 2026 13:30:00 GMT</pubDate>
<description>MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The</description>
</item>
<item>
<title>Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-selected-preliminary-unaudited-213400315</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-selected-preliminary-unaudited-213400315</guid>
<pubDate>Tue, 10 Feb 2026 21:34:00 GMT</pubDate>
<description>All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash</description>
</item>
<item>
<title>Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-participate-piper-sandler-37th-133000364</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-participate-piper-sandler-37th-133000364</guid>
<pubDate>Thu, 20 Nov 2025 13:30:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, De</description>
</item>
<item>
<title>TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression</title>
<link>https://6ix.com/company/neuronetics-inc/news/tricare-west-expands-neurostar-tms-153300060</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/tricare-west-expands-neurostar-tms-153300060</guid>
<pubDate>Wed, 12 Nov 2025 15:33:00 GMT</pubDate>
<description>New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 StatesMALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical policy to includ</description>
</item>
<item>
<title>Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-third-quarter-2025-120500942</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-third-quarter-2025-120500942</guid>
<pubDate>Tue, 04 Nov 2025 12:05:00 GMT</pubDate>
<description>Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restricted cash MALVERN,</description>
</item>
<item>
<title>Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-inducement-grant-under-203000862</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-inducement-grant-under-203000862</guid>
<pubDate>Fri, 31 Oct 2025 20:30:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a mater</description>
</item>
<item>
<title>Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-three-exclusive-partnership-123200169</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-three-exclusive-partnership-123200169</guid>
<pubDate>Thu, 30 Oct 2025 12:32:00 GMT</pubDate>
<description>New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA ClinicsMALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced an exclusive three-year agreement with Elite DNA Behavioral Health</description>
</item>
<item>
<title>Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-report-third-quarter-2025-123000967</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-report-third-quarter-2025-123000967</guid>
<pubDate>Tue, 21 Oct 2025 12:30:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. T</description>
</item>
<item>
<title>New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)</title>
<link>https://6ix.com/company/neuronetics-inc/news/york-state-medicaid-expands-coverage-123200861</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/york-state-medicaid-expands-coverage-123200861</guid>
<pubDate>Wed, 17 Sep 2025 12:32:00 GMT</pubDate>
<description>Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that New York State</description>
</item>
<item>
<title>Neuronetics Reports Second Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-second-quarter-2025-110500010</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-reports-second-quarter-2025-110500010</guid>
<pubDate>Tue, 05 Aug 2025 11:05:00 GMT</pubDate>
<description>Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronet</description>
</item>
<item>
<title>Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-present-canaccord-genuity-45th-203000664</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-present-canaccord-genuity-45th-203000664</guid>
<pubDate>Mon, 04 Aug 2025 20:30:00 GMT</pubDate>
<description>MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Com</description>
</item>
<item>
<title>NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents</title>
<link>https://6ix.com/company/neuronetics-inc/news/neurostar-announces-publication-jaacap-open-123200430</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neurostar-announces-publication-jaacap-open-123200430</guid>
<pubDate>Wed, 30 Jul 2025 12:32:00 GMT</pubDate>
<description>Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes datasetMALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant real-world findings in the Journal of the American Academy of Chil</description>
</item>
<item>
<title>Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-report-second-quarter-2025-123000584</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-report-second-quarter-2025-123000584</guid>
<pubDate>Tue, 22 Jul 2025 12:30:00 GMT</pubDate>
<description>MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The confe</description>
</item>
<item>
<title>Neuronetics Appoints New Chief Financial Officer</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-appoints-chief-financial-officer-113000856</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-appoints-chief-financial-officer-113000856</guid>
<pubDate>Tue, 15 Jul 2025 11:30:00 GMT</pubDate>
<description>Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives</description>
</item>
<item>
<title>Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program</title>
<link>https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-clinical-presence-2025-123100601</link>
<guid isPermaLink="true">https://6ix.com/company/neuronetics-inc/news/neuronetics-announces-clinical-presence-2025-123100601</guid>
<pubDate>Tue, 10 Jun 2025 12:31:00 GMT</pubDate>
<description>NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellenceMALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to cli</description>
</item>
</channel>
</rss>